MedPath

Avitinib

Generic Name
Avitinib
Brand Names
-
Drug Type
-
Chemical Formula
-
CAS Number
-
Unique Ingredient Identifier
-
Indication

用于表皮生长因子受体(EGFR)突变或T790M耐药突变的局部晚期或转移性非小细胞肺癌。

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News
businesskorea.co.kr
·

Chinese Bio Tech Sector Thrives with Record-breaking Exports and Key FDA Approvals

Chinese pharmaceutical and bio industry's technology exports surged to 80 cases in 2022, nearly doubling from 41 in 2021. Major deals include Merck's $9.475 billion investment in Kelun's ADC technology and J&J's CAR-T therapy 'Carvykti' developed with Legend Biotech. FDA approvals for Chinese drugs like Junshi Biosciences' 'Toripalimab' and Bio-Thera Solutions' 'Avitinib' highlight China's growing influence in global bio market.
nature.com
·

Recent advances in targeting the “undruggable” proteins

Covalent inhibitors bind to target proteins via covalent bonds, offering sustained inhibition and longer residence times compared to non-covalent inhibitors. They are effective against undruggable proteins and mutated kinases, exemplified by nirmatrelvir in COVID-19 treatment and sotorasib for KRASG12C mutations. Covalent inhibitors like sotorasib and adagrasib have shown promise in treating cancers with KRAS mutations, overcoming resistance and expanding therapeutic options.

Related Clinical Trials:

Phase 1/2a Study of JAB-21822 Plus JAB-3312 in Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation
A Study of JAB-21822 in Advanced or Metastatic NSCLC With KRAS p.G12C and STK11 Co-mutation and Wild-type KEAP1
JAB-21822 in Combination With Cetuximab in Patients With Advanced CRC and Other Solid Tumors With KRAS G12C Mutation
JAB-21822 Activity in Adult Patients With Advanced Solid Tumors Harboring KRAS G12C Mutation
A Study of JAB-21822 in Adult Patients With Advanced Solid Tumors Harboring KRAS p.G12C Mutation in China
First-in-Human Study of JNJ-74699157 in Participants With Tumors Harboring the KRAS G12C Mutation
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
A Study to Evaluate D-1553 in Combination Therapy in Non-Small Cell Lung Cancer
Study to Evaluate D-1553 in Subjects With Lung Cancer
Study to Evaluate D-1553 in Combination With IN10018 in Subjects With Solid Tumors
Study to Evaluate D-1553 in Subjects With Solid Tumors
Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
Study of JDQ443 in Comparison With Docetaxel in Participants With Locally Advanced or Metastatic KRAS G12C Mutant Non-small Cell Lung Cancer
Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation
A Phase 1 Study to Evaluate the Pharmacokinetics of JDQ443 in Participants With Hepatic Impairment Compared to Matched Healthy Control Participants.
Study of LY3537982 in Cancer Patients With a Specific Genetic Mutation (KRAS G12C)
A Study to Test Different Doses of BI 1823911 Alone and Combined With Other Medicines in People With Different Types of Advanced Cancer With KRAS Mutation
A Phase 1，Open-label Study of BPI-421286 in Subjects With Advanced Solid Tumors
Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors
A Study of [14C]IBI351 in Healthy Subjects
Efficacy and Safety of IBI351 in Combination With Sintilimab ± Chemotherapy in Advanced Non-squamous Non-small Cell Lung Cancer Subjects With KRAS G12C Mutation
A Study of IBI351 in Combination With Cetuximab in Subjects With KRAS G12C Mutated Metastatic Colorectal Cancer
A Study of IBI351 in Healthy Subjects
A Study of IBI351 in Healthy Subjects
A Study to Evaluate Safety and Efficacy of HS-10296 as First-Line Treatment in Patients
Phase I/II Study of CK-101 in NSCLC Patients and Other Advanced Solid Tumors
Phase III Study of Nazartinib (EGF816) Versus Erlotinib/Gefitinib in First-line Locally Advanced / Metastatic NSCLC With EGFR Activating Mutations
Study to Allow Patients Previously Participating in a Novartis Sponsored Trial to Continue Receiving Capmatinib Treatment as Single Agent or in Combination With Other Treatments or the Combination Treatment Alone
To Evaluate the Efficacy and Safety of Anlotinib Combined With Allitinib in Lung Cancer
PH 1 Evaluation Of Oral CI-1033 In Combination With Paclitaxel/ Carboplatin As 1st Line Chemotherapy In NSCLC Patients
A Phase II Study of CI-1033 in Treating Patients With Metastatic (Stage IV) Breast Cancer
A Phase 2, Randomized, Open-Label Study Of Single Agent CI-1033 In Patients With Advanced Non-Small Cell Lung Cancer
A Study of ASP8273 vs. Erlotinib or Gefitinib in First-line Treatment of Patients With Stage IIIB/IV Non-small Cell Lung Cancer Tumors With EGFR Activating Mutations
Study For Patients With NSCLC EGFR Mutations (Del 19 or L858R +/- T790M)
© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy